Skip to Content

AB Concentrated International Growth C CICGX

Medalist Rating as of | See AllianceBernstein Investment Hub
  • NAV / 1-Day Return 10.04  /  +1.31 %
  • Total Assets 184.4 Mil
  • Adj. Expense Ratio
    1.900%
  • Expense Ratio 1.900%
  • Distribution Fee Level Average
  • Share Class Type Level Load
  • Category Foreign Large Growth
  • Investment Style Large Growth
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover 33%

USD | NAV as of May 03, 2024 | 1-Day Return as of May 03, 2024, 10:14 PM GMT+0

Morningstar’s Analysis CICGX

Will CICGX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Weakness in AB Concentrated International Growth C's People and Process Pillar ratings limits this strategy to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CICGX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 47.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Novo Nordisk A/S Class B

7.10 14.4 Mil
Healthcare

ASML Holding NV

6.43 13.0 Mil
Technology

SAP SE

6.05 12.3 Mil
Technology

Compass Group PLC

4.81 9.7 Mil
Consumer Cyclical

Pan Pacific International Holdings Corp

4.35 8.8 Mil
Consumer Defensive

Cellnex Telecom SA

4.31 8.7 Mil
Real Estate

Keyence Corp

3.97 8.1 Mil
Technology

Terumo Corp

3.60 7.3 Mil
Healthcare

Lonza Group Ltd

3.59 7.3 Mil
Healthcare

Fast Retailing Co Ltd

3.30 6.7 Mil
Consumer Cyclical